CLIONA ROONEY to Adoptive Transfer
This is a "connection" page, showing publications CLIONA ROONEY has written about Adoptive Transfer.
Connection Strength
2.594
-
Current challenges for CAR T-cell therapy of acute myeloid leukemia. Transfusion. 2019 04; 59(4):1171-1173.
Score: 0.581
-
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.
Score: 0.233
-
Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol. 2004 Sep; 17(3):401-13.
Score: 0.213
-
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
Score: 0.211
-
Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model. PLoS One. 2015; 10(10):e0140744.
Score: 0.115
-
Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency. J Immunol. 2015 Jun 01; 194(11):5559-67.
Score: 0.112
-
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
Score: 0.098
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.087
-
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010 Mar; 10(3):337-51.
Score: 0.078
-
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
Score: 0.078
-
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
Score: 0.076
-
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
Score: 0.073
-
An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol. 2008 May 01; 180(9):6365-73.
Score: 0.069
-
Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65.
Score: 0.063
-
Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol. 2005 Jan; 128(2):135-44.
Score: 0.055
-
Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol. 2003; 110(2-3):139-48.
Score: 0.048
-
Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease. Acta Haematol. 2003; 110(2-3):149-53.
Score: 0.048
-
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
Score: 0.046
-
The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients. Leuk Lymphoma. 2000 Nov; 39(5-6):455-64.
Score: 0.041
-
Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo. Nat Commun. 2018 04 10; 9(1):1325.
Score: 0.034
-
Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
Score: 0.030
-
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
Score: 0.026
-
Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
Score: 0.026
-
Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
Score: 0.024
-
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012 Sep; 9(9):510-9.
Score: 0.023
-
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010 Nov 25; 116(22):4700-2.
Score: 0.020
-
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
Score: 0.019
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.016
-
Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
Score: 0.016
-
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
Score: 0.015
-
Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004 May 15; 103(10):3979-81.
Score: 0.013
-
Gene-marking and haemopoietic stem-cell transplantation. Blood Rev. 1995 Dec; 9(4):220-5.
Score: 0.007